Literature DB >> 17410107

From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve.

Gerd Meyer zu Hörste1, Hans-Peter Hartung, Bernd C Kieseier.   

Abstract

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy are autoimmune-mediated inflammatory diseases of the PNS. In recent years, substantial progress has been made towards understanding the immune mechanisms that underlie these conditions, in large part through the study of experimental models. Here, we review the available animal models that partially mimic human Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, and discuss the wide range of therapeutic approaches that have been successfully established in these models of inflammatory neuropathies. Transfer of this preclinical knowledge to patients has been far less successful, and inflammatory neuropathies are still associated with significant morbidity and mortality. We will summarize successful therapeutic trials in human autoimmune neuropathies to provide a vantage point for the transfer of experimental treatment strategies to clinical practice in immune-mediated diseases of the peripheral nerve.

Entities:  

Mesh:

Year:  2007        PMID: 17410107     DOI: 10.1038/ncpneuro0452

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  39 in total

Review 1.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

3.  Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Chaoling Dong; Kelsey M Greathouse; Rebecca L Beacham; Steven P Palladino; E Scott Helton; Eroboghene E Ubogu
Journal:  Exp Neurol       Date:  2017-02-16       Impact factor: 5.330

Review 4.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 5.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

6.  Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Authors:  Isaak Quast; Christian W Keller; Michael A Maurer; John P Giddens; Björn Tackenberg; Lai-Xi Wang; Christian Münz; Falk Nimmerjahn; Marinos C Dalakas; Jan D Lünemann
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

Review 7.  The role of chemokines in Guillain-Barré syndrome.

Authors:  Sharon Chiang; Eroboghene E Ubogu
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

8.  The pathogenic relevance of αM-integrin in Guillain-Barré syndrome.

Authors:  Chaoling Dong; Steven P Palladino; Eric Scott Helton; Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2016-07-26       Impact factor: 17.088

Review 9.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  Interleukin-10 overexpression promotes Fas-ligand-dependent chronic macrophage-mediated demyelinating polyneuropathy.

Authors:  Dru S Dace; Aslam A Khan; Jennifer L Stark; Jennifer Kelly; Anne H Cross; Rajendra S Apte
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.